Latanotears

Latanoprost, the active ingredient in Latanotears, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Latanotears as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. Our supply chain ensures product integrity from manufacturing to end‑user, and we provide comprehensive documentation and support for regulatory compliance in each market we serve.

Latanoprost is a prostaglandin analog used to manage ocular pressure in glaucoma and ocular hypertension.

Open‑angle glaucoma: reduces intra‑ocular pressure, thereby slowing optic nerve damage and visual field loss in patients with primary open‑angle glaucoma. Ocular hypertension: lowers elevated intra‑ocular pressure, helping to prevent progression to glaucoma in patients diagnosed with ocular hypertension. Pseudoexfoliative glaucoma: increases uveoscleral outflow to control pressure in pseudoexfoliative (secondary open‑angle) glaucoma, aiding in disease management. Normal‑tension glaucoma: provides pressure reduction that may benefit patients with normal‑tension glaucoma.

Latanotears may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye itching or irritation: transient discomfort. - Increased brown pigmentation of the iris: gradual darkening. - Eyelash growth: longer, thicker lashes.

Serious or Rare Side Effects: - Severe ocular inflammation: uveitis or iritis. - Corneal edema: swelling of the cornea. - Vision loss: sudden decrease in visual acuity.

Before initiating Latanotears, clinicians should consider several safety measures. - Baseline assessment: assess baseline intra‑ocular pressure before therapy. - Monitoring: monitor intra‑ocular pressure regularly after starting treatment. - Infection risk: avoid use in patients with active ocular infection. - Pigmentation changes: inform patients about possible iris color change and that it may be permanent. - Discontinue if severe inflammation occurs. - Store at room temperature: keep in the original container, protect from light and moisture.

Latanotears can interact with other ophthalmic agents, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: may increase risk of ocular side effects. - Combination with carbonic anhydrase inhibitors: additive intra‑ocular pressure lowering effect may cause hypotony.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy of Latanotears. - Beta‑blocker eye drops: additive pressure‑lowering effect, monitor IOP. - Systemic prostaglandin analogs: potential for increased systemic effects.